Treace Medical Concepts closed on a $50 million non-dilutive term loan agreement. After retiring existing term debt, remaining proceeds will fuel the company’s sales, marketing, product development and clinical programs.
The financing will provide Treace with additional growth capital to support commercialization of its Lapiplasty® System, the first procedure that corrects all three dimensions of bunion deformity and creates durable results for patients through a reproducible procedure for physicians.
Treace also announced the expansion of available funds under its existing revolving line of credit to up to $10 million.
Treace Medical Concepts closed on a $50 million non-dilutive term loan agreement. After retiring existing term debt, remaining proceeds will fuel the company's sales, marketing, product development and clinical programs.
Treace Medical Concepts closed on a $50 million non-dilutive term loan agreement. After retiring existing term debt, remaining proceeds will fuel the company’s sales, marketing, product development and clinical programs.
The financing will provide Treace with additional growth capital to support commercialization of its Lapiplasty® System, the first procedure that corrects all three dimensions of bunion deformity and creates durable results for patients through a reproducible procedure for physicians.
Treace also announced the expansion of available funds under its existing revolving line of credit to up to $10 million.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
